2 Reasons to Appreciate ABT and 1 Reason for Caution

Abbott Laboratories: Recent Stock Performance and Investor Considerations

In the past half-year, shares of Abbott Laboratories have dropped to $116.31, resulting in an 11.5% decline. This stands in sharp contrast to the S&P 500, which has risen by 7.7% over the same period. The downturn has been influenced in part by weaker-than-expected quarterly earnings, prompting investors to reassess their strategies.

With the stock under pressure, some may wonder if this presents a buying opportunity for ABT.

What Fuels the Debate Around ABT Shares?

Founded in 1888 by Dr. Wallace Abbott, Abbott Laboratories (NYSE:ABT) has grown into a global healthcare leader, offering a wide array of products spanning medical devices, diagnostics, nutrition, and branded generic medicines.

Key Strengths of Abbott Laboratories

1. Scale Provides Strong Supplier Bargaining Power

Large corporations often benefit from economies of scale, spreading fixed costs such as infrastructure and technology over greater output, which lowers per-unit expenses. This scale can also enhance negotiating power with suppliers, boost brand visibility, and enable greater investment. When managed well, these advantages can reinforce a company’s market position.

Abbott Laboratories generated $44.33 billion in revenue over the past year, demonstrating significant scale. While it may not match the size of industry giants like UnitedHealth Group or The Cigna Group, Abbott’s substantial presence is a major asset in the highly regulated and complex healthcare sector.

2. Strong Free Cash Flow Margin Enables Reinvestment

Free cash flow is a crucial metric, as it reflects a company’s ability to generate cash beyond its operating expenses. This cash can be used for reinvestment or returned to shareholders, making it a key indicator of financial health.

Abbott Laboratories has consistently delivered healthy free cash flow, setting it apart from many competitors. Over the last five years, its average free cash flow margin reached 16.5%, an impressive figure for a healthcare company.

A Notable Concern: Modest Long-Term Revenue Growth

Revenue Expansion Has Lagged

Long-term sales growth is often a sign of a company’s resilience and quality. While short-term gains are possible, sustained expansion is more telling. Unfortunately, Abbott Laboratories has posted a compound annual revenue growth rate of just 5.1% over the past five years, which is relatively modest compared to other healthcare firms. Nonetheless, the company still offers several attractive qualities.

Conclusion: Is Abbott Laboratories a Buy?

Despite some uncertainties, Abbott Laboratories remains a company with significant potential. Following its recent decline, the stock is trading at a forward price-to-earnings ratio of 20.5 (or $116.31 per share). Should investors consider adding ABT to their portfolios?

Other Stocks With Even Greater Potential

Bonus: Top 5 Growth Stocks to Watch

• Many of the market’s top performers shared one trait before their surge: explosive revenue growth. Companies like Meta, CrowdStrike, and Broadcom were all identified early by our AI, delivering returns of 315%, 314%, and 455%, respectively.
• Discover which five stocks are being highlighted this month—at no cost.
• Our recommendations have included well-known names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Kadant, which achieved a 351% five-year return.